Evidence Intelligence™
- EvidenceScore™
- 53
- Emerging
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerResearch Summary
Analyzed using Evidence Intelligence™
IDegLira improves long-term health outcomes and reduces costs for diabetes patients
Last updated June 13, 2026
Key finding
HbA1c decreased by 0.6% (p<0.0001).
This study analyzed the long-term cost-effectiveness of IDegLira for treating type 2 diabetes in China, showing significant improvements in glycemic control and health outcomes.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
Cohort
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
This study analyzed the long-term cost-effectiveness of IDegLira for treating type 2 diabetes in China, showing significant improvements in glycemic control and health outcomes.
Clinical relevance
This research highlights the effectiveness of IDegLira in managing type 2 diabetes, particularly in a population with poor glycemic control. By demonstrating significant reductions in HbA1c and the incidence of complications, this study supports the use of IDegLira as a viable treatment option that could improve patient outcomes and reduce healthcare costs associated with diabetes complications.
Keep in mind
The study may have limited generalizability to populations outside China. Potential unmeasured confounders could affect the outcomes. The analysis did not include long-term follow-up data beyond the initial study period.
Published in
Journal Reference
Publication details and source links for this paper.
Dunming X, Junling W, Lei Z, et al. Long-term cost-effectiveness of IDegLira versus GLP-1RA added to basal insulin regimen for patients with type 2 diabetes in China. PLOS ONE. 2025. doi:10.1371/journal.pone.0310497
Main Effects
HbA1c decreased by 0.6% (p<0.0001)
Systolic blood pressure decreased by 3.5 mmHg (p=0.0017)
Cumulative incidence of eye diseases decreased by up to 41.1%
Cumulative incidence of neuropathy decreased by 17.3%
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to IDegLira and BMI, Diabetic neuropathy incidence, Diabetic retinopathy incidence, and 11 more.
This study contributes evidence to
Primary intervention
IDegLira
Primary outcomes
- BMI
- Diabetic neuropathy incidence
- Diabetic retinopathy incidence
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
14
Evidence pairs
14
Relationships
4
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 72
4
Related topics
14
Evidence pairs
593
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 14 evidence relationships
- Includes primary outcome data
- Linked to 4 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Add related evidence to your Evidence Tracker
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence relationship
GLP-1 Receptor Agonists and HbA1c
Related evidence
Evidence relationship
GLP-1 Receptor Agonists and Cardiovascular Outcomes
Save evidence
Evidence relationship
GLP-1 Receptor Agonists and Body Mass Index
Save evidence
Core evidence
Study findings
The primary outcomes reported in this study.
Diabetic neuropathy incidence
IDegLira → Diabetic neuropathy incidence
IDegLira → Diabetic neuropathy incidence
Evidence Intelligence™
- EvidenceScore™
- 53
- Emerging
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerDiabetic retinopathy incidence
IDegLira → Diabetic retinopathy incidence
IDegLira → Diabetic retinopathy incidence
Evidence Intelligence™
- EvidenceScore™
- 53
- Emerging
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- 53
- Emerging
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- 53
- Emerging
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- 53
- Emerging
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- 53
- Emerging
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerIncidence of heart failure
IDegLira → Incidence of heart failure
IDegLira → Incidence of heart failure
Evidence Intelligence™
- EvidenceScore™
- 53
- Emerging
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerIncidence of macular edema
IDegLira → Incidence of macular edema
IDegLira → Incidence of macular edema
Evidence Intelligence™
- EvidenceScore™
- 53
- Emerging
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerIncidence of myocardial infarction
IDegLira → Incidence of myocardial infarction
IDegLira → Incidence of myocardial infarction
Evidence Intelligence™
- EvidenceScore™
- 53
- Emerging
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- 53
- Emerging
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- 53
- Emerging
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerRenal and urinary disorders incidence
IDegLira → Renal and urinary disorders incidence
IDegLira → Renal and urinary disorders incidence
Evidence Intelligence™
- EvidenceScore™
- 53
- Emerging
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- 53
- Emerging
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Evidence Suggest
- HbA1c decreased by 0.6% (p<0.0001)
- Systolic blood pressure decreased by 3.5 mmHg (p=0.0017)
- Cumulative incidence of eye diseases decreased by up to 41.1%
- Cumulative incidence of neuropathy decreased by 17.3%
Keep in Mind
- The study may have limited generalizability to populations outside China.
- Potential unmeasured confounders could affect the outcomes.
- The analysis did not include long-term follow-up data beyond the initial study period.
Between the Lines
- The study may have limited generalizability to populations outside China.
- Potential unmeasured confounders could affect the outcomes.
- The analysis did not include long-term follow-up data beyond the initial study period.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on GLP-1 Receptor Agonists and Body Mass Index, GLP-1 Receptor Agonists and Neuropathy.
Related evidence relationships
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
GLP-1 Receptor Agonists → Body Mass Index
Medications
Evidence Intelligence™
- EvidenceScore™
- 53
- Emerging
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
View evidenceMedications
GLP-1 Receptor Agonists → Neuropathy
Medications
Evidence Intelligence™
- EvidenceScore™
- 53
- Emerging
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
View evidenceMedications
GLP-1 Receptor Agonists → Blood Pressure
Medications
Evidence Intelligence™
- EvidenceScore™
- 53
- Emerging
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
View evidenceIncluded in these evidence collections
Curated evidence collections and hubs this study is part of.
Blood Pressure Evidence Hub
All studies measuring Blood Pressure
1 studies
outcome_hubMeasures Blood Pressure as a key outcome.
Body Mass Index Evidence Hub
All studies measuring Body Mass Index
1 studies
outcome_hubMeasures Body Mass Index as a key outcome.
GLP-1 Receptor Agonists Evidence Hub
All studies on GLP-1 Receptor Agonists
1 studies
intervention_hubContributes to GLP-1 Receptor Agonists evidence base.
Neuropathy Evidence Hub
All studies measuring Neuropathy
1 studies
outcome_hubMeasures Neuropathy as a key outcome.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explore more in Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on IDegLira and BMI
Intervention: IDegLiraOutcome: BMI
1 results
All studies on IDegLira and Diabetic neuropathy incidence
Intervention: IDegLiraOutcome: Diabetic neuropathy incidence
1 results
All studies on IDegLira
Intervention: IDegLira
1 results
All studies measuring BMI
Outcome: BMI
1 results
All studies measuring Diabetic neuropathy incidence
Outcome: Diabetic neuropathy incidence
1 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does GLP-1 Receptor Agonists improve HbA1c?
Strong Evidence
GLP-1 Receptor Agonists appears to improve HbA1c.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Emerging | EvidenceScore™ 53.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 29 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does GLP-1 Receptor Agonists improve cardiovascular outcomes?
Strong Evidence
GLP-1 Receptor Agonists may improve Cardiovascular Outcomes.
ConsistencyScore™: Results are mixed and should be interpreted cautiously.
Evidence caveat: The available evidence reports mixed findings.
Ranked evidence signals
- 1
Incidence of myocardial infarction
EvidenceScore™ Emerging | EvidenceScore™ 53.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is cautious because the available studies report mixed findings.
Limitations
- Population details are unavailable.
Does GLP-1 Receptor Agonists affect body mass index?
Strong Evidence
GLP-1 Receptor Agonists may improve Body Mass Index.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
BMI
EvidenceScore™ Emerging | EvidenceScore™ 53.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 15 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does GLP-1 Receptor Agonists affect hypoglycemia?
Strong Evidence
GLP-1 Receptor Agonists may improve Hypoglycemia.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Hypoglycemia events
EvidenceScore™ Emerging | EvidenceScore™ 53.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 11 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
GLP-1 agonists reduce heart fat thickness in diabetes.Weight Loss Methods Improve Insulin Resistance in Type 2 DiabetesBariatric surgery reduces CVD risk in type 2 diabetes patients.CBT improves diabetes management in patients with metabolic syndromeCanagliflozin with metformin reduces cardiovascular risk in T2DM
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.